Cancer Treatment Today

The Taxol and Tykerb combination has recently been shown to improve quality of life in metastatic breast cancer patients versus Taxol alone.  In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with Tykerb plus Taxol significantly improved clinical outcomes based on a pre-planned. The combination of investigational Tykerb (lapatinib) and Taxol (paclitaxel) as neoadjuant chemotherapy appears effective against inflammatory breast cancer, according to another small study. There are, as of yet in 2012, no published Phase III studies on survival for this regimen.

NCCN does not list the Taxol/Tykerb regimen.

Read the Professional version here.